In the same article by Dr. Meryl Nass, published on June 27, 2020,139 Nass—who has extensively studied HCQ—pointed out that with prophylactic treatment with HCQ “at the onset of their illness, over 99 percent would quickly resolve the infection, avoiding progression to the late-stage disease characterized by cytokine storm, thrombophilia, and organ failure. Despite claims to the contrary, this treatment is very safe, yet outpatient treatment is banned in the United States.”
